title: Nonventilatory treatments for acute lung injury and ARDS.
abstract: Over the past decade, advances in the ventilatory management of acute lung injury (ALI) and ARDS have improved outcomes; however, until recently the search for other therapies has been less fruitful. Recently, the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment Trial reported that a conservative fluid management strategy, compared with a fluid liberal strategy, increased the mean (+/- SE) number of ventilator-free days in patients with ALI (14.6 +/- 0.5 vs 12.1 +/- 0.5 days, respectively; p < 0.001). In addition to this beneficial effect on outcomes, the study found that the conservative fluid strategy did not increase the incidence of renal failure or the development of shock. Other studies have demonstrated that albumin and furosemide therapy may be beneficial in hypoproteinemic patients with lung injury, though data on outcomes is still lacking. Although several pharmacologic therapies, such as corticosteroids, surfactant, and nitric oxide, have been demonstrated to be ineffective in improving outcomes, several promising new treatments are being investigated in ongoing or upcoming clinical trials. This article reviews these developments and other recent research on the optimal nonventilatory management of patients with ALI.
authors.affiliation: Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California at San Francisco, San Francisco, CA.. Electronic address: carolyn.calfee@ucsf.edu.
authors.forename: Carolyn S
authors.initials: CS
authors.lastname: Calfee
authors.affiliation: Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California at San Francisco, San Francisco, CA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Matthay
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003422:Critical Care / Q000379:methods*; D005440:Fluid Therapy; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007019:Hypoproteinemia / Q000628:therapy; D009569:Nitric Oxide / Q000008:administration & dosage; D011663:Pulmonary Surfactants / Q000008:administration & dosage; D051437:Renal Insufficiency / Q000628:therapy; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000628:therapy*; D012709:Serum Albumin / Q000008:administration & dosage; D012769:Shock / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D011663:Pulmonary Surfactants; D012709:Serum Albumin; D009569:Nitric Oxide; D005665:Furosemide